Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.78 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.78 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.78 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.78 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.78 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.78 |
| ▸ | PTPN11 | Q06124 | 6/20 | 0.74 |
| ▸ | NR0B2 | Q15466 | 3/20 | 0.74 |
| ▸ | RARA | P10276 | 3/20 | 0.62 |
| ▸ | RARG | P13631 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adarotene SCHEMBL29462720 | 1.00 | RARB (1.00) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| Adarotene SCHEMBL403527 | 1.00 | RARB (1.00) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| Adarotene SCHEMBL29449480 | 1.00 | RARB (1.00) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL2405332 | 0.89 | RARB (0.80) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL2389152 | 0.89 | RARB (0.80) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL2389155 | 0.89 | RARB (0.80) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL2405337 | 0.89 | RARB (0.80) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL3295460 | 0.88 | HDAC2 (1.00) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL3295457 | 0.88 | HDAC2 (1.00) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL25870575 | 0.86 | RARB (0.76) | RARBHDAC11HDAC2HDAC7HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160339106-A1 | PRECISE DELIVERY OF THERAPEUTIC AGENTS TO CELL MITOCHONDRIA FOR ANTI-CANCER THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC (US) | 2016-11-24 | — | — | US | claimed |
| EP-3016715-A1 | PRECISE DELIVERY OF THERAPEUTIC AGENTS TO CELL MITOCHONDRIA FOR ANTI-CANCER THERAPY | University Of Georgia Research Foundation, Inc. (US) | 2016-05-11 | — | — | EP | claimed |
| WO-2015002996-A1 | PRECISE DELIVERY OF THERAPEUTIC AGENTS TO CELL MITOCHONDRIA FOR ANTI-CANCER THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-01-08 | — | — | WO | claimed |
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-30 | — | — | US | claimed |
| WO-2010106135-A1 | COMBINED USE FOR THE TREATMENT OF OVARIAN CARCINOMA | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-23 | — | — | WO | claimed |
| EP-2101820-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-09-23 | — | — | EP | claimed |
| WO-2008077772-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-07-03 | — | — | WO | claimed |
| US-20260035353-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | SPECIAL PRODUCTS LINE S P A (IT) | 2026-02-05 | — | — | US | disclosed |
| EP-4661876-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | University of Miami (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168133-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | disclosed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| WO-2007056135-A1 | METHOD OF TREATING CANCERS WITH SAHA AND PEMETREXED | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056162-A2 | METHODS OF TREATING CANCERS WITH SAHA, CARBOPLATIN, AND PACLITAXEL AND OTHER COMBINATION THERAPIES | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056244-A2 | METHODS OF USING SAHA AND ERLOTINIB FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056232-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007022408-A2 | COMBINATION METHODS OF SAHA AND TARGRETIN FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007000383-A1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-01-04 | — | — | WO | disclosed |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035353-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | TLR7, GANC, ARG1 | RARB 2413/4885HDAC11 1114/4885HDAC2 2388/4885 |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | RARA, RARB, RARG | RARB 2/4885HDAC11 883/4885HDAC2 2621/4885 |
| US-20160339106-A1 | PRECISE DELIVERY OF THERAPEUTIC AGENTS TO CELL MITOCHONDRIA FOR ANTI-CANCER THERAPY | SLC25A1, HADHA, CS | RARB 1873/4885HDAC11 1522/4885HDAC2 756/4885 |
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | CXCR4, RARA, CXCL12 | RARB 4/4885HDAC11 1919/4885HDAC2 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.